Latest news with #OBI
Associated Press
15-05-2025
- Business
- Associated Press
OBI Capital Introduces a New Investment Fund Model Combining Real Estate and Blockchain Technology
OBI Capital launches a unique investment fund combining real estate assets with blockchain technology, offering a new opportunity for long-term growth and diversification. United States, May 15, 2025 -- A Fresh Approach to Investment: OBI Capital's Strategy OBI Capital is introducing a new investment fund designed to blend traditional real estate with digital asset investments. This model aims to provide an opportunity for growth by investing in high-performing real estate assets and incorporating blockchain technology for added diversification. By integrating these two asset classes, OBI Capital seeks to offer a more balanced and structured approach to long-term investment. Unlike traditional financial institutions that may prioritize institutional investors, OBI Capital has structured this fund to be more accessible, enabling a broader range of individuals to engage with both real estate and digital assets as part of their investment strategy. Real Estate and Blockchain: A Dual Investment Strategy The fund primarily focuses on investing in real estate properties, such as apartment buildings, which are selected for their long-term appreciation potential. These properties are expected to provide steady rental income, which is then reinvested into a diversified portfolio of digital assets, including cryptocurrencies such as Bitcoin, Ethereum, Cardano, XRP, and Chainlink. This dual approach aims to balance the stability of real estate with the growth potential of digital assets. The strategy is designed to reduce risk by carefully selecting both real estate and cryptocurrency investments, providing investors with a diversified portfolio that aligns with their long-term goals. The Team Behind OBI Capital: Expertise in Real Estate and Blockchain OBI Capital was founded by Amir Yazdani, an experienced professional in both real estate and blockchain technology. Amir and his team have previously launched OBICOIN, a utility token designed for use in real estate transactions, and established the OBI Real Estate platform, which streamlined property transactions by integrating cryptocurrency payments. The OBI Capital team brings their expertise in blockchain technology and real estate management to this new fund, drawing on their experience to create a structure designed for consistent growth and risk mitigation. Access to Investment: Tokenized Participation with Lower Entry Requirements One of the distinguishing features of OBI Capital is its lower entry point for individual investors. The fund allows tokenized participation starting at $1,000, providing a way for more people to access the opportunity to invest in both real estate and digital assets. This model contrasts with traditional investment funds, which often require significant capital commitments and may be inaccessible to many potential investors. This structure aims to offer a more inclusive approach to wealth-building, giving individuals who might not have had access to these investment opportunities the ability to participate in both real estate and digital assets. OBI Capital's Long-Term Vision: Expanding Global Opportunities Looking forward, OBI Capital plans to expand its portfolio of properties and further diversify its digital asset holdings. With a scalable structure and a commitment to compliance, the fund aims to provide long-term investment opportunities while responding to the changing landscape of both real estate and blockchain technologies. OBI Capital seeks to position itself as a competitive alternative to traditional investment models by offering a diversified, stable approach to wealth-building. Its focus on real estate and digital assets reflects its long-term vision to meet the evolving needs of investors in a global financial market. About OBI Capital OBI Capital is an innovative investment fund that combines real estate and blockchain technology to provide investors with a diversified portfolio designed for long-term growth. The fund invests in high-performing real estate assets while integrating digital assets such as cryptocurrencies to offer both stability and growth. OBI Capital's team has a proven track record in both real estate and blockchain, having previously launched OBICOIN and the OBI Real Estate platform. The fund's focus is on providing accessible investment opportunities for a broad range of investors. Media Contact Adriana OBI Capital Contact Info: Name: Adriana Email: Send Email Organization: OBI Capital Website: Disclaimer: This press release is for informational purposes only. Information verification has been done to the best of our ability. Still, due to the speculative nature of the blockchain (cryptocurrency, NFT, mining, etc.) sector as a whole, complete accuracy cannot always be guaranteed. You are advised to conduct your own research and exercise caution. Investments in these fields are inherently risky and should be approached with due diligence. Release ID: 89159945 If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.
Yahoo
05-05-2025
- Business
- Yahoo
FDA clears OBI Pharma's IND to begin Phase I/II solid tumour trial
OBI Pharma has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application for OBI-902 to commence a Phase I/II trial for treating individuals with advanced solid tumours. The clinical trial is set to commence subject enrolment in the second half of this year. The trop-2 antibody-drug conjugate (ADC), OBI-902, employs the company's GlycOBI ADC enabling technology, offering hydrophilicity and stability. Trop-2 is known to be highly expressed in numerous solid tumour types, including ovarian, breast, and gastric cancers. The ADC is said to carry a topoisomerase I inhibitor payload with a drug-antibody ratio (DAR) of four, designed to target and destroy tumour cells. With its enhanced pharmacokinetic characteristics, this site-specific glycan-conjugated ADC is claimed to have shown antitumor efficacy and a favourable safety profile in several animal models. OBI Pharma CEO Heidi Wang said: 'The impending OBI-902-001 clinical trial intends to evaluate the safety, pharmacokinetics, and preliminary efficacy of OBI-902 in patients with advanced solid tumours. We are very excited to begin dosing patients in our Phase I/II clinical study of OBI-902 later this year.' Since December 2021, the company has licenced Trop-2 targeting antibody from the biotech company Biosion, securing the exclusive global rights, with the exception of China. OBI has global commercial rights to OBI-902, except for the rights pertaining to the antibody in China. The company noted that its GlycOBI platform is compatible with various antibodies, payloads, and linkers. Leveraging EndoSymeOBI and HYPrOBI, the company's enzymatic and linker technologies, respectively, the GlycOBI platform produces homogenous ADCs that are site-specific, under good manufacturing practice (GMP) conditions. The GlycOBI conjugation process preserves the antibody structure, ensuring that the ADC maintains biophysical characteristics akin to the native antibody. OBI's linker technology is claimed to have enhanced the payload conjugation efficiency and minimised aggregation propensity, offering manufacturing advantages for ADC products. Additionally, the company has further developed the ThiOBI platform to enable irreversible cysteine-based conjugation. "FDA clears OBI Pharma's IND to begin Phase I/II solid tumour trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23-04-2025
- Business
- Yahoo
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI's novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed using the next generation proprietary GlycOBI® technologies. OBI-902 demonstrated superior antitumor activity and favorable PK/PD properties compared to benchmark TROP2 ADCs across various animal models. OBI-992, a cysteine-based TROP2 targeting ADC, demonstrated a differentiated resistance profile compared to benchmark ADCs. Additionally, characterization and non-clinical in vivo data will be presented for the glycan-specific GlycOBI® and cysteine-based ThiOBI® proprietary ADC platforms, highlighting enhanced antitumor activity and stability in animal model studies. ThiOBI® is a new next-generation platform and adds to OBI's armamentarium of ADC enabling technologies. Additionally, the non-clinical and antitumor activity of OBI-3424, a novel AKR1C3 targeted prodrug, will be presented. Furthermore, the potential correlation between GH expression and poor prognosis in cholangiocarcinoma (CCA), along with GH's role in modulating immune responses in CCA patients will be discussed. These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 25 to 30, 2025 in Chicago, Illinois (USA). 'Our data demonstrated that OBI-902, derived from a site-specific GlycOBI® platform, showed favorable PK and differentiated profiles with good ADC stability in circulation, and efficient payload release in the tumor site of tumor bearing mouse. In the xenograft models, OBI-902 demonstrated both superior and more durable antitumor activity compared to benchmark ADCs. The GlycOBI® platform represents a breakthrough in antibody-drug conjugate (ADC) development as a distinct glycan site-specific technology, enabling a versatile drug-antibody ratio (DAR) and dual payload conjugations. The GlycOBI® platform consists of both EndoSymeOBI® enzyme and HYPrOBI™ linker technologies. The EndoSymeOBI® dual function enzyme technology enables a precise glycan remodeling for site-specific conjugation through a 'one-pot' process. The HYPrOBI™ technology provides a masking effect to reduce payload hydrophobicity, while the shielding effect enhances controlled payload release, specifically in tumor environments to prevent premature release in circulation. Notably, this technology can achieve a drug-antibody ratio (DAR) as high as 16, which is the highest DAR that can be achieved in site-specific glycan platforms.' said OBI's Chief Scientific Officer, Ming-Tain Lai, Ph.D. 'Furthermore, the ThiOBI® platform was developed utilizing an irreversible cysteine conjugation alongside the HYPrOBI™ technology, to improve stability and prevents premature payload release. ADCs derived from the ThiOBI® platform demonstrated superior antitumor activity compared to traditional cysteine benchmark ADCs.' In collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, Pediatric Preclinical In Vivo Testing (PIVOT) Program, OBI-3424 was evaluated for its antitumor activity across a panel of pediatric hepatoblastoma PDX models by PIVOT research teams at Memorial Sloan-Kettering Cancer Center and the University of Texas Health Science Center at San Antonio, yielding promising results. Monday, April 28,2025 Title: OBI-992, a novel TROP2 antibody-drug conjugate, exhibits distinct resistance profiles compared to other TROP2 targeting ADCs 1 Authors: Lifen Shen, Tzer-Min Kuo, Yu-Hsuan Tsao, Ya-Chi Chen, Ming-Tain Lai. OBI Pharma, Inc, Taipei, Taiwan Session Title: PO. ET03.06 - Drug Resistance in Molecular Targeted Therapies 2Location: Poster Section 20Poster Board Number 3Abstract Presentation Number 1702Session Date and Time: Monday April 28, 2025. 9:00 AM - 12:00 PM Title: Harnessing the GlycOBI® enabling technologies: next-generation site-specific glycan ADCs with versatile DAR to enhance therapeutic index 2 Authors: Teng-Yi Huang, Ka-Shu Fung, Yu-Chao Huang, Chi-Sheng Shia, Chi-Huan Lu, Nan-Hsuan Wang, Ya-Chi Chen, Ming-Tain Lai. OBI Pharma, Inc, Taipei, Taiwan Session Title: - Novel Drug Delivery TechnologiesLocation: Poster Section 23Poster Board Number 18Abstract Presentation Number 1799Session Date and Time: Monday, April 28, 2025. 9:00 AM - 12:00 PM Tuesday, April 29, 2025 Title: OBI-902, a novel TROP2 targeted antibody-drug conjugate via GlycOBI® platform, has favorable pharmacokinetics and sustained antitumor activities in challenging solid tumors. 3 Authors: Ren-Yu Hsu, Chi-Huan Lu, Chi-Sheng Shia, Hsin-Shan Wu, Lu-Tzu Chen, Jhih-Jie Yang, Jyy-Shiuan Tu, Hui-Wen Chang, Shih-Ni Wen, Ming-Tain Lai, Ya-Chi Chen. OBI Pharma, Inc., Taipei, Taiwan Session Title: - Pharmacokinetics and Pharmacodynamics of Cancer TherapeuticsLocation: Poster Section 20Poster Board Number: 21Abstract Presentation Number: 4356Session Date and Time: Tuesday, April 29, 2025. 9:00 AM - 12:00 PM Title: Globo H Affects the immune tumor microenvironment in cholangiocarcinoma 4 Authors: Chih Chieh Yen, Tzer Min Kuo, Chun Jung Lin, Hung Wen Tsai, Wen Lung Wang, Chien Jui Huang, Ping Jui Su, Ting Kai Liao, I Ting Liu, Li Chin Cheng, Ying Jui Chao, Yan Shen Shan, Chia Jui Yen, Ming Tain Lai. National Cheng Kung University Hospital, Tainan, Taiwan, OBI Pharmaceuticals Inc., Taipei, Taiwan, National Cheng Kung University Hospital, Tainan, Taiwan, National Cheng Kung University Hospital, Tainan, Taiwan, National Cheng Kung University Hospital, Tainan, Taiwan, Chi Mei Medical Center, Tainan, Taiwan Session Title: - Molecular Diagnosis, Molecular Characterization and Theranostics of TumorsLocation: Poster Section 30Poster Board Number: 17Abstract Presentation Number: 4597Session Date and Time: Tuesday, April 29, 2025. 9:00 AM - 12:00 PM Title: ThiOBI® platform, a novel hydrophilic linker for irreversible cysteine-selective biomolecular conjugation, demonstrated potent and durable antitumor activities in various animal models 5 Authors: Yu-Chao Huang, Ting-Wei Liu, Chi-Huan Lu, Ren-Yu Hsu, Nan-Hsuan Wang, Ya-Chi Chen, Ming-Tain Lai, Teng-Yi Huang. OBI Pharma, Inc, Taipei, Taiwan Session Title: - Novel Methods in Small Molecule and Biologics Drug DiscoveryLocation: Poster Section 22Poster Board Number: 20Abstract Presentation Number: 5675Session Date and Time: Tuesday, April 29, 2025. 2:00 PM - 5:00 PM Title: Potentiation of AKR1C3- and P53-dependent AST-3424* activity via PUMA-mediated degradation of Rad51 6 Authors: Jianxin Duan, Tianyang Qi, Yizhi Wang, Xing Liu, Zhaoqiang Lu, Jibing Yu, Xiaohong Cai, Anrong Li, Don Jung, Chen Xun, Yanbin Xie, Fanying Meng, Shukui Qin. Ascentawits Pharmaceuticals, LTD, Shenzhen, China, The First Affiliated Hospital of China Pharmaceutical University, Nanjing Tianyinshan Hospital, Hepatobiliary and Pancreatic Tumor Department., Nanjing, China, GI Cancer Center, Nanjing Tianyinshan Hospital affiliated to China Pharmaceutical University, Nanjing, China Session Title: - Novel Antitumor Agents 3Location: Poster Section 21Poster Board Number: 27Abstract Presentation Number: 5649Session Date and Time: Tuesday, April 29, 2025. 2:00 PM - 5:00 PM Wednesday, April 30,2025 Title: Preclinical evaluation of the AKR1C3-activated alkylator OBI-3424 in hepatoblastoma: A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT) 7Authors: Filemon Dela Cruz, Andrew Kung, Raushan Kurmasheva, Peter Houghton, Daoqi You, Glorife Ibanez Sanchez, Steven Neuhauser, Tim Stearns, Jeff Chuang, Jee Young Kwon, Emily L. Jocoy, Yu-Jung Chen, Ming-Chen Yang, Beverly Teicher, Carol J. Bult, Malcolm A. Smith. Memorial Sloan Kettering, New York, NY, UT Health San Antonio, San Antonio, TX, The Jackson Laboratory, Bar Harbor, ME, The Jackson Laboratory, Farmington, CT, The Jackson Laboratory, Sacramento, CA, OBI Pharma, Taipei City, Taiwan, National Cancer Institute, Bethesda, MD, National Cancer Institute, Bethesda, MD Session Title: - Advances in Translational Pediatric Cancer ResearchLocation: Poster Section 28Poster Board Number 20Abstract Presentation Number 7050Session Date and Time: Wednesday, April 30, 2025. 9:00 AM - 12:00 PM The e-posters will be available for browsing at the AACR Annual Meeting beginning at 12:00 PM ET on April 25, as well as on the OBI Pharma website ( beginning on May 1. 1 AACR Annual Meeting 2025 Abstracts online AACR Annual Meeting 2025 Abstracts online AACR Annual Meeting 2025 Abstracts online AACR Annual Meeting 2025 Abstracts online AACR Annual Meeting 2025 Abstracts online AACR Annual Meeting 2025 Abstracts online AACR Annual Meeting 2025 Abstracts online About OBI Pharma OBI Pharma, Inc., is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission is to develop novel cancer therapeutic agents for patients with high unmet medical needs. Using the company's proprietary ADC enabling technologies, GlycOBI®, powered by EndoSymeOBI® and HYPrOBI™; OBI has created its novel ADC pipeline, including OBI-992, OBI-902, and OBI-904, targeting TROP2 and Nectin-4, respectively. To broaden the applicability of the linker technology, HYPrOBI™, OBI further developed a next-generation ThiOBI® platform to enable cysteine-based conjugation. Additionally, the company's novel first-in-class immuno-oncology portfolio targeting Globo H includes: two Globo H active immunotherapy vaccines, adagloxad simolenin (formerly OBI-822) and OBI-833. OBI's pipeline also includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at About OBI-992 and OBI-902 OBI-992 and OBI-902 are TROP2-targeted antibody-drug conjugates (ADCs) that carries a potent topoisomerase I inhibitor payload to kill tumor cells. TROP2 is highly expressed in a variety of solid tumors such as lung, breast, ovarian, and gastric cancer, rendering it an ideal target for cancer therapy. OBI-992 uses a unique hydrophilic, enzyme-cleavable linker that is stable in circulation but releases the cytotoxic payload inside tumor cells. OBI-902 is a novel site-specific glycan ADC using OBI proprietary GlycOBI® platform with improved stability and hydrophilicity. Both OBI-992 and OBI-902 demonstrated remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. OBI-992 received US IND clearance in December 2023 and Phase 1/2 efficacy and safety human studies are ongoing. IND of OBI-902 was submitted to FDA on March 31st, 2025. The TROP2 targeting antibody was in-licensed from Biosion, Inc. in December 2021. OBI Pharma owns ex-China commercial rights for OBI-992. *About OBI-3424OBI-3424 is a first-in-class novel chemotherapeutic prodrug by OBI Pharma, Inc. that is selectively converted by AKR1C3 to a potent DNA-alkylating agent that leads to selective killing of cancer cells. The Company acquired the worldwide rights (except for China, Hong Kong, Macao, Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey, and India; owned by Ascentawits as AST-3424) of OBI-3424 from Threshold Pharmaceuticals, Inc. in 2017. OBI-3424 has been granted Orphan Drug Designation for the treatment of Hepatocellular Carcinoma (HCC) and Acute Lymphoblastic Leukemia (ALL) by the US FDA in 2018. OBI Pharma, Inc. continues the collaboration of OBI 3424 with Ascentawits through the sharing of clinical data and information. About GlycOBI® OBI has developed a unique glycan ADC platform (GlycOBI®), which are in a 'Plug and Play' format and compatible with any antibodies, linkers, and payloads in various Drug antibody ratio (DAR). Utilizing OBI's proprietary enzymatic technology (EndoSymeOBI®) and linker technology (HYPrOBI™), GlycOBI® generates site-specific homogenous ADCs with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI's linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity, and also expanded the half-life of the ADC products. GlycOBI® has overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo tests. GlycOBI ® and EndoSymeOBI ® are registered trademarks of OBI Pharma. Inc. HYPrOBI™ is a trademark under registration. About ThiOBI® OBI has developed a novel irreversible cysteine conjugation ADC platform (ThiOBI®) with improved stability, which can apply to any antibodies, linkers, and payloads. Utilizing OBI's proprietary ThiOBI® platform including linker technologies (HYPrOBI™) can generate ADCs in different biomolecular formats, including antibody fragments, nanobodies, peptides, and proteins. Furthermore, OBI's HYPrOBI™ linker technology has improved conjugation efficiency of the payload and reduced aggregation propensity, and also expanded the half-life of the ADC products. ThiOBI® has overcome the limitations of traditional cysteine ADCs and achieved better antitumor activity and stability in various in vivo tests. ThiOBI® is a registered trademark of OBI Pharma. Inc. Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Bureau. COMPANY CONTACT:Kevin Poulos, CBOOBI Pharma, Inc.1.619.537.7698 Ext. 102kpoulos@ in to access your portfolio
Forbes
25-03-2025
- Business
- Forbes
20 Questions To Ensure The Quality Of AI-Generated Content
Given AI's ability to churn out content quickly, it's crucial for brands and their agency partners to ensure AI-generated content meets their quality standards. While using AI for writing can be efficient, it often requires human intervention to ensure it sounds authentic to a brand, resonates with readers and provides real value. With careful review and intentional refinement, AI can be a powerful ally in creating meaningful, engaging content. Below, members of Forbes Agency Council share key questions they recommend content writers ask before publishing any piece of AI-generated content to ensure it hits all the right notes. AI speeds the path to publication, but it's only as effective as the human mind reviewing it. Make sure it feels authentic and sounds like the person, brand or business it reflects. Tailor it so that it resonates with the audiences it is intended for. With a critical eye and a human touch, GenAI tools can be a content writer's best friend. - Mary Ann O'Brien, OBI Creative AI can generate text, but it's up to writers to ensure it provides real value, feels human and meets the reader's needs. Content should inform, engage and connect—not just exist for the sake of publishing. - Abbi Whitaker, The Abbi Agency Content writers should ask, 'If I changed the brand name in this content, would it still apply without requiring edits?' If the answer is 'yes,' the content should be reworked. Does it sound like your client's brand in tone, voice and style? Do the data points or examples apply specifically to the client's brand? If the answer is 'no,' the content should be refined to ensure alignment. - Bernard May, National Positions AI is still learning, and it is only as good as the information it's been fed, so humans need to ensure content is true to the spirit of its purpose and has enough humanity to be meaningful. Further, a real person is required to fact-check the content produced by AI, as AI is able to parrot information but isn't currently able to distinguish if that information is accurate. - Chintan Shah, KNB Communications Forbes Agency Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify? Too many times, writers publish content that doesn't align with—or even worse, contradicts—previous opinions they've shared as individuals and/or as a brand. It is fine to evolve and change your mind, but it's important to note that you changed your mind, not AI. - Vix Reitano, Agency 6B Asking if it's worth reading—and sharing—is the best way to address the user experience of your content. Considering it from the audience perspective gives you an opportunity to look beyond accuracy and branding so that you can use written content to position yourself as an expert and build loyalty. - Marc Hardgrove, The HOTH Focusing on providing unique value ensures the piece includes human insight, expertise and originality, making it more engaging, credible and useful to readers. AI should enhance content, not replace critical thinking or authenticity, helping brands maintain trust and authority in their industry. - Scott Keever, Keever SEO It's important to have a checklist of items to review before publishing an AI-generated piece, including checks for accuracy, tone, alignment with the brand and so on. The key question to ask that is often forgotten is: Has the majority of this information been published before? - Susan Thomas, 10Fold Communications One question to ask is: 'Does this align with our brand's voice, guidelines and accuracy standards and our audience's needs?' Content writers should always fact-check, refine and personalize AI-generated content before hitting 'Publish.' - David Ispiryan, Effeect AI engines can occasionally have issues with properly including links and quality sources in content, which are extremely important for SEO. Additionally, having proper keyword density in articles can sometimes be a challenge for AI engines, so this is crucial for content marketers to double-check. - William Gasner, Stack Influence Would this be embarrassing if I said it out loud? Would I proudly defend it to a national audience? Does it sound like something that anyone else in my industry could say, or is it unique to me? If it's not valuable, unique and worth standing behind, it's not worth publishing. - Curtis Priest, Pixelcarve Inc. AI has changed how we produce content, but it's not always accurate or up to date. Sometimes, AI will provide a list of closed restaurants or decade-old facts. Human review ensures credibility, relevance and expert insight, helping to maintain trust and authority in your content. - Jonathan Schwartz, Bullseye Strategy One question writers should ask is if the AI-generated content will resonate with the target audience and meet their expectations. AI can certainly generate compelling content, but it ultimately falls short when compared to human-written content. - Jordan Edelson, Appetizer Mobile LLC Would you say this? If the answer to this fundamental question is 'no' for any reason, then you should be stepping in as the 'human in the loop' and figuring out how to make it a 'yes.' Fact-checking, doing more research and adding nuance to a point of view will likely flip a generic, not useful or hallucinated piece of AI-generated content into something you'd put your name behind. - Starr Million Baker, INK Communications Co. AI-generated content often recycles overused anecdotes and generic data that won't set you apart. Including personal insights and original ideas adds a fresh perspective and makes the content authentic, which is far more relatable. It's your unique signature that turns a piece of AI-generated content into something worthy of reading. - Ayelet Noff, SlicedBrand AI often hallucinates, producing outputs that seem believable but may not reflect reality. It's essential to ensure the content aligns with what's true for regular people in the real world, as AI can create convincing but false narratives, even in legal or factual contexts. - Austin Irabor, NETFLY If you strictly want to add more keywords to a site or increase your client's digital footprint with content for the sake of having content, AI-generated pieces can be effective. However, if your goal is to create meaty, compelling content that consumers engage with on a more meaningful level, it's worth taking the time to write it yourself. - Evan Nison, NisonCo AI can churn out words, but if it reads like a robot wrote it, you've already lost. Before hitting 'Publish,' writers should check for authenticity, nuance and a real, engaging voice. If it feels stiff, generic or soulless, tweak it. Readers connect with personality, not predictability—so make sure it passes the human vibe check. - Justin Belmont, Prose Content writers need to ask themselves, 'How does this AI-generated content help to achieve my marketing goals?' All too often, AI-generated content is used because it's easy to generate, rather than because it helps move customers along their buying journey. - Mike Maynard, Napier Partnership Limited AI can generate words, but real insights make people stop and think. If content doesn't challenge assumptions, offer a unique perspective or provide genuinely useful information, it's just noise. Would this content grab your attention if you stumbled across it? If not, refine it until it sparks curiosity and delivers real value. - Dmitrii Kustov, Regex SEO
Yahoo
18-02-2025
- Climate
- Yahoo
Got Blood? OBI needs donors as blood shortage continues
WICHITA FALLS (KFDX/KJTL) — Our Blood Institute is asking the community to consider donating blood as impending weather could cause the loss of hundreds of blood units. There is a blood shortage, and the incoming cold weather could cause OBI to lose over 100 units within the next week. They are urgently seeking donors, and this is how you can help. There will be two blood drives on Tuesday, Feb. 18. Locations are Kell West Regional Hospital Blood Drive, Tuesday, Feb. 18, 10 a.m. to 1 p.m. and YMCA Bill Bartley Branch Blood Drive, Tuesday, Feb. 18, 3:30 p.m. to 6:30 p.m. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
